![OncLive SOSS (@onclivesoss) 's Twitter Profile](https://pbs.twimg.com/profile_images/824355045005283337/EWEUtf7y_200x200.jpg)
OncLive SOSS
@onclivesoss
Premier oncology summits that focus on the most relevant cancer topics to ultimately improve patient care. #OncLiveIPC
ID: 824013573873668096
http://www.onclive.com/meetings/soss 24-01-2017 21:58:40
25,25K Tweet
2,2K Takipçi
746 Takip Edilen
![OncLive SOSS (@onclivesoss) 's Twitter Profile Photo OncLive SOSS (@onclivesoss) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/824355045005283337/EWEUtf7y_200x200.jpg)
Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy and the potential role of biomarkers in future targeted treatments. #kcsm ow.ly/m3Gr50OIF2r
![OncLive SOSS (@onclivesoss) on Twitter photo Brian I. Rini, MD, of <a href="/VUMC_Cancer/">Vanderbilt-Ingram Cancer Center</a>, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy and the potential role of biomarkers in future targeted treatments. #kcsm ow.ly/m3Gr50OIF2r Brian I. Rini, MD, of <a href="/VUMC_Cancer/">Vanderbilt-Ingram Cancer Center</a>, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy and the potential role of biomarkers in future targeted treatments. #kcsm ow.ly/m3Gr50OIF2r](https://pbs.twimg.com/media/FyHMqPMXoAMvfWR.jpg)